RxDoctor Payments DataLook up a doctor →

Nicolas Nammour, MD

Neurology · Houston, TXNPI 1962426692

Payments from drug & device makers

$842,005in general payments, 2019–2025

Across 2,750 payments — averaging $306.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$371K
  • Pfizer$187K
  • Biohaven Pharmaceutical Holding Company Ltd.$85K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$81K
  • Novartis$40K
  • Biohaven Pharmaceuticals, Inc.$21K
  • plus $56K from 54 others
$24,868in research payments, 2019–2025

Across 12 payments — averaging $2072.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$25K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)590$370,858
Pfizer163$187,347
Biohaven Pharmaceutical Holding Company Ltd.84$85,432
Otsuka Pharmaceutical Development & Commercialization, Inc.5$81,042
Novartis144$39,719
Biohaven Pharmaceuticals, Inc.45$20,949
Avanir Pharmaceuticals, Inc.8$18,080
EMD Serono, Inc.94$3,341
UCB, Inc.115$2,882
Medtronic(2 entities)31$2,197
Abbott64$2,117
Boston Scientific61$1,876
AstraZeneca(2 entities)71$1,664
Biogen97$1,650
Sanofi57$1,189
Acadia Pharmaceuticals Inc66$1,137
CSL Behring56$1,076
Teva Pharmaceuticals USA, Inc.60$1,059
Genentech USA, Inc.66$1,031
Sunovion Pharmaceuticals Inc.57$1,001
Amneal Pharmaceuticals LLC58$915
Eisai Inc.59$907
Lilly USA, LLC51$801
SK Life Science, Inc.42$770
Lundbeck LLC44$767
Takeda Pharmaceuticals U.S.A., Inc.28$728
Grifols USA, LLC24$708
Argenx US, Inc.27$708
Neurocrine Biosciences, Inc.30$653
Supernus Pharmaceuticals, Inc.23$591
Amgen25$555
Sumitomo Pharma America, Inc.27$514
Merz Pharmaceuticals, LLC19$490
MDD US Operations, LLC24$478
Bristol Myers Squibb24$446
Johnson & Johnson(2 entities)22$387
Kyowa Kirin, Inc.18$383
Adamas Pharmaceuticals, Inc.17$381
Otsuka America Pharmaceutical, Inc.21$379
TG Therapeutics, Inc.19$379
Catalyst Pharmaceuticals, Inc.14$296
Axsome Therapeutics, Inc.10$285
Tanabe Pharma America, Inc.14$280
Banner Life Sciences, LLC16$268
Neurelis, Inc.10$247
Arbor Pharmaceuticals, Inc.14$236
Acorda Therapeutics, Inc11$220
Scilex Pharmaceuticals Inc.9$170
Corium, LLC7$162
Jazz Pharmaceuticals Inc.5$154
Vertiflex, Inc.4$148
GE HealthCare5$144
Impel Pharmaceuticals Inc.8$137
Merz North America, Inc.5$124
Microtransponder, Inc.4$123
Aquestive Therapeutics, Inc.7$113
Livanova USA, Inc.5$104
Upsher-smith Laboratories LLC6$95
Vertical Pharmaceuticals, LLC4$80
Zyla Life Sciences, Inc.5$76

How this compares

$842,005 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$449,177
Medicare patients
697
Services billed
22,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →